This list is an analysis based on recent market events. It's not an investment recommendation.
About
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy program for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
The current price of ACOG.V is C$0.24 CAD — it has increased by +0% in the past 24 hours. Watch Alpha Cognition stock price performance more closely on the chart.
What is Alpha Cognition stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alpha Cognition stocks are traded under the ticker ACOG.V.
What is Alpha Cognition revenue for the last year?▼
Alpha Cognition revenue for the last year amounts to 0 CAD.
What is Alpha Cognition net income for the last year?▼
ACOG.V net income for the last year is -24.65M CAD.
In which sector is Alpha Cognition located?▼
Alpha Cognition operates in the Healthcare sector.
When did Alpha Cognition complete a stock split?▼
Alpha Cognition has not had any recent stock splits.
Where is Alpha Cognition headquartered?▼
Alpha Cognition is headquartered in Vancouver, CA.